Characterization of the sex-specific pattern of angiogenesis and lymphangiogenesis in aortic stenosis.

angiogenesis aortic stenosis lymphangiogenesis sex valve interstitial cells

Journal

Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388

Informations de publication

Date de publication:
2022
Historique:
received: 17 06 2022
accepted: 11 08 2022
entrez: 29 9 2022
pubmed: 30 9 2022
medline: 30 9 2022
Statut: epublish

Résumé

We aim to analyze sex-related differences in angiogenesis and lymphangiogenesis in aortic valves (AVs) and valve interstitial cells (VICs) from aortic stenosis (AS) patients. Totally 230 patients (59% men) with severe AS undergoing surgical valve replacement were recruited. The density of total neovessels was higher in AVs from men as compared to women. Both small and medium neovessels were more abundant in men's AVs. Accordingly, male AVs exhibited higher CD31 and VE-cadherin expressions. The levels of the pro-angiogenic markers, such as vascular endothelial growth factor (VEGF)-A, VEGF receptor (VEGFR)1, VEGFR2, insulin-like growth factor-binding protein-2 (IGFBP-2), interleukin (IL)-8, chemerin, and fibroblast growth factor (FGF)-7, were increased in AVs from men. Transforming growth factor-β expression was higher in male AVs. The expression of antiangiogenic molecules thrombospondin (Tsp)-1, endostatin, and CD36 was upregulated in male AVs, although the levels of Tsp-2, IL-4, IL-12p70, and chondromodulin-1 were similar between both sexes. The number of lymphatic vessels and the expression of the lymphangiogenic markers Lyve-1 and D2-40 was higher in men's AV as well as VEGF-C, VEGF-D, and VEGFR3. Multivariate analyses adjusted for confounders further validated the sex-dependent expression of these targets. VICs isolated from men's AVs secreted higher amounts of the pro-angiogenic factors, VEGF-A, VEGFR1, IGFBP-2, and FGF-7, as well as the pro-lymphangiogenic factors, VEGF-C, VEGF-D, and VEGFR3, than women without changes in antiangiogenic markers. Our data show that aberrant angiogenic and lymphangiogenic cues are over-represented in male AVs. Importantly, the VIC is a relevant source of multiple morphogens involved in angiogenesis and lymphangiogenesis likely endowing the AV of men with the predominant calcific AS phenotypes.

Identifiants

pubmed: 36172587
doi: 10.3389/fcvm.2022.971802
pmc: PMC9510663
doi:

Types de publication

Journal Article

Langues

eng

Pagination

971802

Informations de copyright

Copyright © 2022 Matilla, Martín-Núñez, Garaikoetxea, Navarro, Vico, Arrieta, García-Peña, Fernández-Celis, Gainza, Álvarez, Sádaba, López-Andrés and Jover.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Cardiovasc Med. 2022 Feb 24;9:818371
pubmed: 35282345
Front Cardiovasc Med. 2021 Aug 30;8:736303
pubmed: 34527715
Sci Rep. 2017 Jul 14;7(1):5443
pubmed: 28710369
Circulation. 2005 Jun 21;111(24):3296-301
pubmed: 15956138
Hypertension. 2022 Aug;79(8):1724-1737
pubmed: 35549329
Int J Cardiol. 2021 Sep 15;339:128-129
pubmed: 34293365
Arthritis Res. 2001;3(3):147-53
pubmed: 11299055
Circulation. 2006 Mar 14;113(10):1344-52
pubmed: 16534030
Eur Heart J. 2019 Jan 7;40(2):79-80
pubmed: 30615155
Atherosclerosis. 2012 Jan;220(1):66-71
pubmed: 22035575
Ann Biomed Eng. 2016 Sep;44(9):2707-23
pubmed: 26905695
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):415-429
pubmed: 33147990
Cesk Patol. 2010 Apr;46(2):33-6
pubmed: 21275223
Lipids Health Dis. 2008 Jan 29;7:2
pubmed: 18230165
PLoS One. 2015 Jun 04;10(6):e0127844
pubmed: 26042674
Clin Orthop Relat Res. 1992 Feb;(275):287-99
pubmed: 1735227
Hum Pathol. 2003 Aug;34(8):756-63
pubmed: 14506635
Trends Cell Biol. 2010 Sep;20(9):556-67
pubmed: 20656490
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E363-E371
pubmed: 29282325
PLoS One. 2012;7(7):e39980
pubmed: 22808080
J Clin Invest. 1993 Apr;91(4):1800-9
pubmed: 8473518
J Cardiovasc Dev Dis. 2021 Jun 25;8(7):
pubmed: 34202041
Circ Res. 2017 Feb 17;120(4):681-691
pubmed: 27879282
Int J Biochem Cell Biol. 2004 Jun;36(6):1115-25
pubmed: 15094126
Exp Cell Res. 2004 Aug 15;298(2):455-64
pubmed: 15265693
Circ Res. 2005 May 13;96(9):930-8
pubmed: 15890980
J Am Heart Assoc. 2016 Nov 4;5(11):
pubmed: 27815266
J Clin Invest. 2016 Feb;126(2):509-26
pubmed: 26731472
Atherosclerosis. 2012 Apr;221(2):366-74
pubmed: 22281299
Eur Heart J. 2021 Jul 15;42(27):2683-2691
pubmed: 34023890
Eur J Clin Invest. 2011 May;41(5):487-97
pubmed: 21128936
Cell Stem Cell. 2015 Jan 8;16(1):51-66
pubmed: 25465115
Science. 1997 May 30;276(5317):1423-5
pubmed: 9162011
Cell Stem Cell. 2016 Nov 3;19(5):628-642
pubmed: 27618218
Cold Spring Harb Perspect Biol. 2011 Oct 01;3(10):a009712
pubmed: 21875984
Nat Immunol. 2004 Jan;5(1):74-80
pubmed: 14634646
Circ Cardiovasc Imaging. 2013 Jan 1;6(1):40-7
pubmed: 23233744
Endocrinology. 2000 May;141(5):1667-74
pubmed: 10803575
PLoS One. 2011;6(11):e27743
pubmed: 22110751
Circ Res. 2022 Feb 18;130(4):455-473
pubmed: 35175844
Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1220-7
pubmed: 20299690
Ann Thorac Surg. 2003 Feb;75(2):457-65; discussion 465-6
pubmed: 12607654
Nat Med. 1999 Jun;5(6):623-8
pubmed: 10371499

Auteurs

Lara Matilla (L)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Ernesto Martín-Núñez (E)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Mattie Garaikoetxea (M)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Adela Navarro (A)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Julieta Anabela Vico (JA)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Vanessa Arrieta (V)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Amaia García-Peña (A)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Amaya Fernández-Celis (A)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Alicia Gainza (A)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Virginia Álvarez (V)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Rafael Sádaba (R)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Natalia López-Andrés (N)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Eva Jover (E)

Cardiovascular Translational Research, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.

Classifications MeSH